Management of type-1 and type-2 diabetes by insulin injections in diabetology clinics - a scientific research review

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 6, Issue 2, 2012, Pages 148-170

  Aziz, Kamran M A ^a  

^a ASEER CENTRAL HOSPITAL   (Saudi Arabia)

Author keywords

DKA; HbA1c; Insulin resistance; MDI; OHA; SMBG; Type 1 DM; Type 2 DM

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SHORT ACTING INSULIN; SULFONYLUREA;

ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; DEMOGRAPHY; DIABETIC KETOACIDOSIS; DRUG DELIVERY SYSTEM; DRUG INDICATION; EVIDENCE BASED MEDICINE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MOLECULAR BIOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT MONITORING; PHARMACODYNAMICS; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

EID: 84861790826     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221412800604608     Document Type: Article

References (258)

1. World Health Organization (WHO). Report of a WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications.1. Diagnosis and classification of diabetes mellitus. WHO/NCD/NCS/99.2. Geneva: WHO, 1999.NCD/NCS/99.2. Geneva: WHO, 1999.
2. Himsworth HP. Diabetes Mellitus: Its differentiation into insulin sensitive and insulin-insensitive types. Lancet 1936; 1:117.
3. Rademacher, T.W. Materials and methods relating to the diagnosis and treatment of diabetes and obesity.US6716592 (2004).
4. Bronstein J, Lawrence RD. Plasma insulin in human diabetes mellitus. BMJ 1951; 2:1541.
5. Berson SA, Yalow RS. Antigens in insulin determinants of specificity of procaine insulin in man. Science 1963;139:844.
6. Schober, A. Method for the simultaneous measurement of antigens and their antibodies by solid phase radioimmunoassay. US4172117 (1979).
7. Coffey, J.W. Radioimmunoassay for insulin. US3867518 (1975).
8. Langerhans P. Beitrage zur mikroskopischen Anatomie der Bauchspeicheldruse. Inaugural dissertation, Gustav Lange ed. 1869.
9. Banting FG, Best CH. The internal secretion of the pancreas. J Lab Clin Med 1922; 7:251-66.
10. Albisser, A.M. Treatment of diabetes using phosphorylated insulin. US5242900 (1993).
11. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus: preliminary report. Can Med Assoc J 1922; 12: 141-6.
12. Roberts F. Letter. From the discovery of insulin by Michael Bliss. Br Med J 1922; 1193-4.
13. World Health Organization (WHO) Expert Committee on Diabetes Mellitus. First Report: Technical Report Series 310. Geneva: WHO, 1964.
14. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-57.
15. World Health Organization (WHO) Expert Committee on Diabetes Mellitus. Second Report: Technical Report Series 646. Geneva: WHO, 1980.
16. World Health Organization (WHO). Diabetes Mellitus: Report of a Study Group. Technical Report Series 727. Geneva: WHO, 1985.
17. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197.
18. Fryburg, D.A., Gibbs, E.M., Koppiker, N.P. Treatment of diabetes mellitus. US6683080 (2004).
19. Piper, B.A. Method for treating diabetes. US7598262 (2009).
20. Wagner, D.H. Methods for distinguishing type-1 from type-2 diabetes. US0234316 (2006).
21. Bigley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale EA. Prediction of IDDM in the general population: Strategies based on combinations of autoantibody markers. Diabetes 1997; 46:1701.
22. Bach JF. Etiology and pathogenesis of human insulin-dependent diabetes mellitus. In: Volpe R, Ed Autoimmune endocrinopathies. Totowa, NJ: Humana Press, 1999:293-307.
23. Barker JM, Barriga KJ, Yu L, Miao D, Erlich HA, Norris JM, et al. Prediction of Autoantibody Positivity and Progression to Type 1 Diabetes. Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004 89: 3896-902.
24. Soeldner JS, Steinke J. Insulin resistance. Med Clin North Am 1965; 49: 939-46.
25. Reaven GM, Bernstein R, Davis B, Olefsky JM. Non ketotic diabetes mellitus: insulin deficiency or insulin resistance? Am J Med 1976; 60:80-88.
26. DeFronzo RA. The triumvirate: Beta-cell, muscle, liver: A collusion responsible for NIDDM. Diabetes 1988; 37:667-87.
27. Burcelin R, Knauf C, Cani PD. Pancreatic alpha-cell dysfunction in diabetes. Diabetes Metab 2008; 34 (Suppl 2):S49-55.
28. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011; 34(Suppl. 1):S62-9.
29. Moalem S, Storey KB, Percy ME, Peros MC, Perl DP. The sweet thing about Type 1 diabetes: A cryoprotective evolutionary adaptation. Medical Hypotheses (2005) 65, 816. Available at: http://intl.elsevierhealth.com/journals/mehy (Accessed on: June 20, 2010).
30. Karvonen J, Toumilehto J, Libman I, LaPorte R, for the World Health Organization DIAMOND Project Group. A review of the recent epidemiological data on the world wide incidence of type-1 (insulin dependent) diabetes mellitus. Diabetologia 1993;36:883.
31. King H, Aubert RA, Herman WH. Global burdren of diabetes, 1995-2025. Prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414.
32. Harris MI, Cowie CC, Reiber G, Boyko E, Stern M, Bennett P, eds. Diabetes in America, 2nd ed. Washington DC: U.S. Government Printing Office, 1995.
33. Yasuda, K., Kasuga, M., Kadowaki, T., Furuta, H., Makino, H., Yamagata, K. Tests methods for type-2 diabetes using gene polymorphism. US0151456 (2011).
34. Hutton JC. Insulin secretory granule biogenesis and the proinsulin processing endopeptidases. Diabetologia 1994; 37 (Suppl 2): S48-S56.
35. Jonassen, I., Clausen, I.G., Jensen, E.B., Svendsen, A. Insulin precursors. US5202415 (1993).
36. Andrali SS, Sampley ML, Vanderford NL, Ozcan S. Glucose regulation of insulin gene expression in pancreatic beta - cells. Biochem J 2008; 415: 1-10.
37. Ashcroft SJ, Bunce J, Lowry M, Hansen SE, Hedeskov CJ. The effect of sugars on (pro)insulin biosynthesis Biochem J 1978; 174: 517-26.
38. Van SE. Short term regulation of glucokinase. Diabetologia 1994; 37(Suppl 2): S43-7.
39. Newgard, C.B., Jensen, P.B. Gene products that regulate glucose response in cells. US0148421 (2003).
40. Thulé, P.M. Glucose sensitive regulation of Insulin transcription. US7790690 (2010).
41. Muoio DM, Newgard CB. Mechanisms of disease: Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9:193-205.
42. Rea S, James DE. Moving GLUT-4: The biogenesis & trafficking of GLUT-4 storage vesicles. Diabetes 1997; 46:1667.
43. Shephered PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: The key switch mechanism in insulin signaling. Biochem J 1998; 333:471.
44. Shepred PR, Kahn BB. Glucose transporters & insulin action: Implications for IR & DM. N Engl J Med 1999; 341:248.
45. Kauvar, L.M., Sportsman, R., Villar, H.O., Spevak, W.R., Kohanski, R.A., Satyam, A., Koehler, R. Modulators of insulin receptor activity. US0078188 (2003).
46. Vaag A, Henriksen JE, Beck-Nielsen H. Decreased insulin activation of glycogen synthase in skeletal muscles in young non-obese Caucasian first-degree relatives of patients with non-insulindependent diabetes mellitus. J Clin Invest 1992; 89:782-8.
47. Salonen, J.T., Aalto, J.M., Fuentes, R., Kontkanen, O., Pirskanen, M., Uimari, P. Novel genes and markers associatedto type-2 diabetes mellitus. US0059722 (2007).
48. Salonen, J.T., Aalto, J.M., Fuentes, R., Kontkanen, O., Pirskanen, M., Uimari, P. Method for detecting the risk of and for treatment of type-2 diabetes. US0059722 (2007).
49. Kusari J, Verma US, Buse JB, Henry RR, Olefsky JM. Analysis of the gene sequences of the insulin receptor & insulin sensitive glucose transporter (GLUT-4) in patients with common NIDDM. J Clin Invest 1991;88:1323.
50. Vogt B, Mühlbacher C, Carrascosa J, Obermaier-Kusser B, Seffer E, Mushack J, et al. Subcellular distribution of Glut-4 in the skeletal muscle of lean type-2 (NID) diabetic patients in the basal state. Diabetologia 1992; 35:456.
51. Carey JO, Azevedo JL Jr, Morris PG, Pories WJ, Dohm GL. Okadaic acid, Vanadate, & phenylarsine oxide stimulate 2- deoxyglucose transport in insulin resistant human skeletal muscle. Diabetes 1995; 44(6):682.
52. Azevedo JL Jr, Carey JO, Pories WJ, Morris PG, Dohm GL. Hypoxia stimulates glucose transport in insulin resistant human skeletal muscle. Diabetes 1995; 44(6):695.
53. Houmard JA, Egan PC, Neufer PD, Friedman JE, Wheeler WS, Israel RG, et al. Elevated skeletal muscle glucose transporter levels in exercise trained middle ages men. Am J Physiol 1991;261:E437.
54. Dela F, Ploug T, Handberg A, Petersen LN, Larsen JJ, Mikines KJ, et al. Physical training increase muscle GLUT-4 protein & mRNA in patients with NIDDM. Diabetes 1994; 43:862.
55. Andersen PH, Lund S, Schmitz O, Junker S, Kahn BB, Pedersen O. Increased insulin stimulated glucose uptake in athletes: the importance of GLUT-4 mRNA, GLUT-4 protein & fibre type composition of skeletal muscle. Acta Physiol Scand 1993; 149:393.
56. Garvey WT, Maianu, Huecksteadt TP, Birnbaum MJ, Molina JM, Ciaraldi TP. Pre-translational suppression of a glucose transporter protein causes IR in adipocytes from patients with NIDDM & obesity. J Clin Invest 1991; 87:1072.
57. Rosenbaum D, Haber RS, Dunaif A. Insulin resistance in polycystic ovary syndrome: Decreased expression of GLUT-4 glucose transporter. Am J Physiol 1993; 264:E197.
58. Garvey WT, Maianu L, Zhu JH, Hancock JA, Golichowski AM. Multiple defects in adipocyte glucose transport system cause cellular IR in GDM: Heterogeneity in the number & a novel defect in sub cellular distribution of the insulin responsive GLUT-4 isoform. Diabetes 1993; 42:1773.
59. Bergman RN, Ader M, Huecking K, Citters GV. Accurate assessment of -cell function: The hyperbolic Correction. Diabetes 2002; 51 (Suppl 1):S212-20.
60. Henquin JC, Ishiyama N, Nenquin M, Ravier MA, Jonas JC.Signals and pools underlying biphasic insulin secretion. Diabetes 2002; 51 (Suppl 1):S60-7.
61. Penner, R., Fleig, A. Methods of screening for TRPM4 modulators of insulin secretion. US0039336 (2008).
62. Haeften TW. Early disturbances in insulin secretion in the development of type 2 diabetes mellitus. Mol Cell Endocrinol 2002;197:197-204
63. Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? Diabetes 2002; 51 (Suppl 1):S117-21.
64. Henriksen JE, Alford F, Handberg A, Vaag A, Ward GM, Kalfas A, et al. Increased glucose effectiveness in normoglycemic but insulin-resistant relatives of patientswith non-insulin-dependent diabetes mellitus. A novel compensatory mechanism. J Clin Invest 1994; 94:1196-204.
65. Solimena, M., Mziauf, H., Trajkovski, M. ICA512 couples insulin secretion and gene expression in beta-cells. US0131309 (2009).
66. Lee, S.C., Chan, J.C., Critchley, J.A., West, C.P., Cockram, C.S. Methods and compositions for evaluation risk of developing type-2 diabetes in people of Chinese descent. US0089852 (2005).
67. Hoffmann, J.A. GLP-1 formulations. US6358924 (2002).
68. Sugita, K., Kasahara, S., Ebinuma, H., Takaiwa, F., Jomori, T., Hayashi, Y. GLP-1 derivative. US7847063 (2010).
69. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53.
70. Giorgino F, Laviola L, Leonardini A. Pathophysiology of type 2 diabetes: Rationale for different oral antidiabetic treatment strategies. Diabetes Res Clin Pract 2005; 68 (Suppl1):S22-9.
71. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218
72. Poitout V, Robertson RP: Glucolipotoxicity: Fuel excess and betacell dysfunction. Endocr Rev 2008; 29:351-66.
73. Strasser, A., McKenzie, M., Thomas, H., Allison, J., Kay, T. Methods of treating and preventing glucose toxicity.US0256152 (2011).
74. Unger RH, Zhou YT, Orci L. Regulation of fatty acid homeostasis in cells: Novel role of leptin. Proc Natl Acad Sci USA 1999;96:2327-32.
75. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: Many differences, few similarities. Diabetes 2005; 54 (Suppl 2):S97-107.
76. Yamashita T, Eto K, Okazaki Y, Yamashita S, Yamauchi T, Sekine N, et al. Role of uncoupling protein-2 up-regulation and triglyceride accumulation in impaired glucose-stimulated insulin secretion in a beta-cell lipotoxicity model overexpressing sterol regulatory element-binding protein-1c. Endocrinology 2004;145:3566-77.
77. Rosskamp, R., Gersten, H. Methods for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type-2 diabetes. US0287343 (2008).
78. Unger RH, Grundy S. Hyperglycemia as an inducer as well as a consequence of impaired islet cell function. & IR. Diabetologia 1985; 28:119.
79. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987; 79:1510.
80. Vuorinen-Markkola H, Koivisto VA, Yki-Jarvinen H. Mechanisms of hyperglycemia induced IR in whole body & skeletal muscle of type-1 DM pts. Diabetes 1992; 41:571.
81. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3:153-65.
82. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. Determinants of the impaired secretion of glucagonlike peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;.86:3717-23.
83. Pfeifer MA, Halter JB, Porte D Jr. Insulin secretion in diabetes mellitus. Am J Med 1981; 70:579-88.
84. Weber B. Glucose-stimulated insulin secretion during "remission" of juvenile diabetes. Diabetologia 1972; 8:189-95.
85. Johansen K, Ørskov H. Plasma insulin during remission in juvenile diabetes mellitus. BMJ 1969; 1:676-8.
86. Block MB, Rosenfield RL, Mako ME, Steiner DF, Rubenstein AH. Sequential changes in beta-cell function in insulin-treated diabetic patients assessed by C-peptide immunoreactivity. N Engl J Med 1973; 288:1144-8.
87. Park BM, Soeldner JS, Gleason RE. Diabetes in remission. Insulin secretory dynamics. Diabetes 1974; 23:616-23.
88. Ludvigsson J, Heding LG. Beta-cell function in children with diabetes. Diabetes 1978; 27(Suppl 1):230-4.
89. Carlstrom S, Ingemanson CA. Juvenile diabetes with long-standing remission. A case report. Diabetologia 1967; 3:465-7.
90. Heding LG, Ludvigsson J, Kasperska-Czyzykowa T. βCell secretion in non-diabetics and insulin-dependent-diabetics. Acta Med Scand 1981 (Suppl); 656:5-9.
91. Ludvigsson J, Heding L. Abnormal proinsulin/C-peptide ratio in juvenile diabetes. Acta Diabet Lat 1982; 19:351-8.
92. Snorgaard O, Hartling SG, Binder C. Proinsulin and C-peptide at onset and during 12 months cyclosporin treatment of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990; 33:36-42.
93. Srikanta S, Ganda OP, Jackson RA, Gleason RE, Kaldany A, Garovoy MR, et al. Type I diabetes mellitus in monozygotic twins: chronic progressive beta cell dysfunction. Ann Intern Med 1983;99:320-6.
94. Klöppel G, Löhr M, Habich K, Oberholzer M, Heitz PU. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 1985; 4:110-25.
95. Koenig, S. Methods for the treatment of LADA and other adult onset autoimmune using immunosuppressive monoclonal antibodies with reduced toxicity. US0015142 (2010).
96. Perego, C., Cairano, E.S., Davalli, A., Folli, F. Methods and compositions for the diagnosis and treatment of diabetes. US0244486 (2011).
97. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 1737-54.
98. Krentz AJ, Bailey CJ. Oral antidiabetic agents: Current role in type 2 diabetes mellitus. Drugs 2005; 65:385-411.
99. Lebovitz HE. Insulin secretagogues: Old and new. Diabetes Rev 1999; 7: 139-51.
100. Rendell M. The role of sulfonylureas in the management of type 2 diabetes. Drugs 2004; 64: 1339-58.
101. Schlichtkrull J, Brange J, Christiansen AH, Hllund O, Heding LG, Jorgensen KH. Clinical aspects of insulin antigenicity. Diabetes 1972; 21 (Suppl 2): 649-56.
102. Jackson, R.L. Process for purifying Insulin. US3878186 (1975).
103. Morihara, K., Oka, T., Soejima, M., Masaki, T. Semi-synthesis of human insulin. US4401757 (1983).
104. Chien YW. Human insulin: Basic sciences to therapeutic uses. Drug Dev Ind Pharm 1996; 22: 753-89.
105. Markussen, J., Fiil, N., Hansen, M.T., Norris, K., Annerer, G., Thim, L., Voigt, H.O. DNA-sequence encoding biosynthetic insulin precursors and process for preparing the insulin precursors and human insulin. US4916212 (1990).
106. Herler, J.M., Copenhagen, N.F., Hensen, M.T., Birkerod, K.N., Gentofte, L.T., Lyndby, H. Biosynthetic insulin precursors and process for preparing the insulin precursors and human insulin.US4916212 (1990).
107. Lazaryev, A.P., Markussen, J., Fiil, N., Hansen, M.T., Norris, K., Annerer, G., Thim, L., Voigt, H.O., Luciv, V.R., Kostetskii, I.E., Lisovskyy, I.L., Lesik, I.P. Method for producing human recombinant insulin. US0058513 (2012).
108. Berger W, Keller U, Honegger B, Jaeggi E. Warning symptoms of hypoglycaemia during treatment with human and porcine insulin in diabetes mellitus. Lancet 1989; 1: 1041-4.
109. Teuscher A, Berger WG. Hypoglycaemia unawareness in diabetics transferred from beef/porcine insulin to human insulin. Lancet 1987; 2: 382-5.
110. Richter B, Neises G. "Human" insulin versus animal insulin in people with diabetes mellitus. Cochrane Database Syst Rev 2005; 1: 003816.
111. Airey CM, William DR Martin PG, Bennett CM, Spoor PA. Hypoglycemia induced by exogeneous insulin: "human" and animal insulin compared. Diabet Med 2000; 17: 416-32.
112. Bauman L. Clinical experience with globulin insulin. Proc Soc Exp Biol Med 1939; 40: 170-1.
113. Hagedorn HC, Jensen BN, Krarup NB, Woodstrup I. Protamin insulinate. JAMA 1936; 106: 177-80
114. Jackson, R.L. Protamine insulin product. US3868358 (1975).
115. Olsen, H.B., Balschmidt, P., Kaarsholm, N.C., Jakobsen, P. Novel NPH insulin preparation. US20060258561(2006).
116. Brader, M.L. Insoluble insulin composition. US006465426 (2002).
117. Hallas, M.K., Peterson, K., Schlichtkrull, J. Crystalline and amorphous insulin - zinc compounds with prolonged action. Ugeskr Laeger 1951; 113: 1761-7.
118. Hoffmann, J.A. Insulin formulation. US005534488 (1996).
119. Langballe, P., Norup, E. Stabilezed insulin compositions. US6174856 (2001).
120. Søeborg T, Rasmussen CH, Mosekilde E, Colding-Jørgensen M. Absorption kinetics of insulin after subcutaneous administration. Eur J Pharm Sci 2009; 36: 78-90.
121. Brange J, Owens DR, Kang S, Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 923-54.
122. Kang S, Brange J, Burch A, Volund A, Owens DR. Subcutaneous insulin absorption explained by insulin' s physiochemical properties. Diabetes Care 1991; 14: 942-8.
123. Heinemann L, Heise T, Jorgensen LN, Starke AA. Action profile of the rapid acting insulin analogue: Human insulin B28Asp. Diabet Med 1993; 10: 535-39.
124. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys (B28), Pro (B29)] - Human insulin: A rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.
125. Olsen, H.B., Kjeldsen, T.B., Balschmidt, P., Glendorf, T., Havelund, S. Rapid acting insulin analogues. US0021423 (2011).
126. Langkjaer, L. Novel insulin formulations. US0261168 (2005).
127. Hirsch IB. Insulin analogues. N Engl J Med 2005; 352: 174-83.
128. Messadek, J. Insulin combinations. US7786077 (2010).
129. Bode BW. Use of rapid - acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: Insulin pump therapy versus multiple daily injections. Clin Ther 2007; 29 (Suppl D): S135-44.
130. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984; 7:188-99.
131. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125 I - labeled insulin glargine (HOE 901) in healthy men: Comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000; 23: 813-9.
132. Monami M, Marchionni N, Mannucci E. Longacting insulin analogues versus NPH human insulin in type 2 diabetes: A meta - analysis. Diabetes Res Clin Pract 2008; 81: 184-9.
133. Lee WL, Zinman B. From insulin to insulin analogs: Progress in the treatment of type 1 diabetes. Diabetes Rev 1998; 6:73-88.
134. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999; 22 (Suppl 2):B109-B13.
135. Luzio SD, Owens D, Evans M, Ogunku A, Beck P, Kurzhals R. Comparison of the sc absorption of insulin glargine (HOE 901) and NPH human insulin type 2 diabetic subjects. Diabetes 1999; 48(Suppl 1):A111.
136. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-9.
137. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000; 23:639-43.
138. Rosenstock J, Park G, Zimmerman J, US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000;23:1137-42.
139. Yki-Järvinen H, Dressler A, Ziemen M. HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000; 23:1130-6.
140. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obesity 2004;28 (Suppl 2): S23-8.
141. Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 1999;16:332-8.
142. Barnett AH. A review of basal insulins. Diabet Med 2003; 20:873-85.
143. Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: A randomized clinical trial. Diabetes Care 2004;27(5):1081-7.
144. Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590-6.
145. Becker, R., Frick, A., Boderke, P., Müller, W., Werner, U., Loss, P. Long acting formulations of insulin. US0301081 (2011).
146. Habermann, P., Seipke, G., Kurrle, R., Muller, G., Sommerfeld, M., Werner, U. Novel insulin derivatives havingextremely delayed time action profile. US0077197 (2011).
147. Jonassen, I., Jansen, T.H., Havelund, S., Madsen, U.R., Tagmose, T.M., Madsen, P. Novel insulin derivatives. US0009899 (2010).
148. Mudaliar SR, Lindberg FA, Joyce M, Rave K, Hompesch B, Sedlak M, et al. Insulin aspart: A fast acting analog of human insulin-absorption kinetics and action profile compared with regular human insulin in healthy non-diabetic subjects. Diabetes Care 1999; 22:1501-6.
149. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE 901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23:644-9.
150. Adapted from Heineman L, Richter B. Clinical pharmacology of human insulin. Diabetes Care 1993; 16(Suppl S3):90-101.
151. Rubenstein AH, Spitz I. Role of the kidney in insulin metabolism and excretion. Diabetes 1968; 17:161-9.
152. Duckworth WC. Insulin degradation: Mechanisms, products, and signifi cance. Endocr Rev 1988; 9: 319-4.
153. WHO Expert Committee on Diabetes Mellitus. Education. Second report. Technical report series 646. Geneva: World Health Organization, 1980:58.
154. Mensing C, Boucher J, Cypress M, Weinger K, Mulcahy K, Barta P, et al. National standards for diabetes self-management education. Diabetes Care 2000; 23:682-9.
155. American Diabetes Association. Insulin administration: Position statement. Diabetes Care 2004; 27(Suppl 1):S106.
156. Strauss K. Insulin injection techniques. Pract Diabetes Int 1998; 15: 181-4.
157. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the diabetes control and complications trial. Diabetes 1997; 46:271-86.
158. McCrimmon RJ, Frier BM. Hypoglycemia, the most feared complication of insulin therapy. Diabet Metab 1994; 20:503-12.
159. The Diabetes Control and Complications Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995; 18:1415-27.
160. Gerich JE, Campbell PJ. Overview of counter regulation and its abnormalities in diabetes mellitus and other conditions. Diabetes Metab Rev 1988; 4:93-111.
161. Reeves WG, Allen BR, Tattersall RB. Insulininduced lipoatrophy: Evidence for an immune pathogenesis. Br Med J 1980; 280: 1500-3.
162. Young RJ, Hannan WJ, Frier BM, Steel JM, Duncan LJ. Diabetic lipohypertrophy delays insulin absorption. Diabetes Care 1984; 7: 479-80.
163. Diabetes education goals. Alexandria, VA: American Diabetes Association, 2002.
164. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care 2000; 23:381-9.
165. Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999; 22:345-54.
166. Fagot-Campagna A. Emergence of type 2 diabetes mellitus in children: Epidemiological evidence. J Pediatr Endocrinol Metab 2000; 13(Suppl 6):1395-402.
167. Fagot-Campagna A, Pettitt DJ, Engelgau MM, Burrows NR, Geiss LS, Valdez R, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 2000; 136:664-72.
168. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2004; 27(Suppl 1):S15-S35.
169. Lean ME, Ng LL, Tennison BR. Interval between insulin injection and eating in relation to blood glucose control in adult diabetics. BMJ (Clin Res Ed) 1985; 290:105-8.
170. Sackey AH, Jefferson IG. Interval between insulin injection and breakfast in diabetes. Arch Dis Child 1994; 71:248-50.
171. Somogyi M. Insulin as a cause of extreme hyperglycemia and instability. Bull St Louis Med Soc1938; 32:498-500.
172. Bolli GB, Gerich JE. The dawn phenomenon--a common occurrence in both non-insulindependent and insulin-dependent diabetes mellitus. N Engl J Med 1984; 310(12):746-50.
173. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: National clinical guideline management in primary and secondary care (update). London: Royal College of Physicians, 2008.
174. Heise T, Weyer C, Serwas A, Heinrichs S, Osinga J, Roach P, et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998; 21: 800-3.
175. Kovisto VA, Tuominen JA, Ebeling P. Lispro mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 1999; 22:459-62.
176. Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999; 22:1258-61.
177. Kapitza C, Rave K, Ostrowski K, Heise T, Heinemann L. Reduced postprandial glycaemic excursion with biphasic insulin Aspart 30 injected immediately before a meal. Diabet Med 2004;21:500-1.
178. Coscelli C, Calabrese G, Fedele D, Pisu E, Calderini C, Bistoni S, et al. Use of premixed insulin among the elderly. Diabetes Care 1992; 15:1628-30.
179. Bohannon NJV. Insulin delivery using pen devices: Simple-to-use tools may help young and old alike. Postgrad Med 1999:106(5):57-68.
180. Valensi P. Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes. Diabetes Metab Syndr Obes 2009:2 61-71.
181. Chen JW, Lauritzen T, Bojesen A, Christiansen JS. Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal bolus human insulin treatment in patients with type 1 diabetes. Diabetes Obes Metab 2006; 8(6):682-9.
182. Skyler JS. Insulin therapy in type 1 diabetes mellitus. In Current Therapy of Diabetes Mellitus. DeFronzo RA, Ed. St. Louis, MO, Mosby, 1998; 36-49.
183. Zinman B. The physiologic replacement of insulin. N Engl J Med 1989; 321:363-70.
184. DeWitt DE, Hirsch IB. Outpatient insulin treatment in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 2003; 289:2254-64.
185. Dall V. Preclinical safety pharmacology studies on the rapid-acting insulin analogue, insulin aspart. Artzneim Forsch Drug Res 1999; 49: 463-70.
186. Mortensen HB, Lindholm A, Olsen BS, Hylleberg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr 2000: 159: 483-8.
187. Holcombe JH, Zalani S, Arora VK, Mast CJ. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther 2002: 24: 629-38.
188. Riddle MC. Evening insulin strategy. Diabetes Care 1990; 13: 676-86.
189. DeWitt DE, Dugdale DC. Using new insulin strategies in the outpatient treatment of diabetes mellitus: Clinical applications. JAMA 2003; 289:2265-9.
190. Anderson JH Jr, Brunelle RL, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, et al. Reduction of postprandial hyperglycemia and frequency hypoglycemia in IDDM patients on insulin-analogue treatment. Diabetes 1997; 46:265-70.
191. Hirsch IB, Farkas-Hirsch R, Skyler JS: Intensive insulin therapy for treatment of type 1 diabetes. Diabetes Care 1990; 13:1265-83.
192. Schade DS, Santiago JV, Skyler JS, Rizza R. Intensive insulin therapy. Princeton, NJ, Excerpta Med, 1983.
193. NICE. (National Institute of Clinical Excellence). Guidance on the use of long-acting insulin analogs for the treatment of diabetesinsulin glargine. Technology Appraisal Guidance No 53. 2002. Available at: http://guidance.nice.org.uk/TA53/guidance/pdf/ English (Accessed on: July 6, 2010).
194. Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type-1 diabetes. Diabetes 2004: 53: 1614-20.
195. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogs (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004: 47: 622-9.
196. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet Med 2007: 24: 27-34.
197. Zinman B.The physiologic replacement of insulin. N Engl J Med 1989; 321:363-70.
198. Seipke G, Geisen K, Neubauer HP, Pittius C, Rosskamp R, Schwabe D. New insulin preparations with prolonged action profiles: A21-modified arginine insulin. Diabetologia 1992; 35 (Suppl 1): A4-A5.
199. Heineman L, Linkescowa R, Rave K, Hompesh B, Sedlak M, heise T. Time-action profile of the longacting insulin analog glargine (HOE 901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23: 644-9.
200. Robenstock J, Park G, Zimmerman J, for the US insulin glargine (HOE 901) type 1 diabetes investigator group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000; 23: 1137-42.
201. Bloomgarden ZT. American Diabetes Association Annual Meeting, 1999: New approaches to insulin treatment and glucose monitoring. Diabetes Care 1999; 22: 2078-2082.
202. McCassey K, Perlman K, Daneman D. Insulin therapy in children and adolescents with type-1 diabetes. Diab Nutr Metab 1999; 12: 86-95.
203. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
204. Deeb LC, Holcombe JH, Brunelle R, Zalani S, Brink S, Jenner M, et al. Insulin lispro lowers postprandial glucose in prepubertal children with diabetes. Pediatrics 2001: 108: 1175-9.
205. Holcombe JH, Zalani S, Arora VK, Mast CJ. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther 2002: 24: 629-38.
206. Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004: 53: 1614-20.
207. DCCT. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr 1994; 125: 177-88.
208. De Beaufort CE, Houtzagers CM, Bruining GJ, Aarsen RS, Den Boer NC, Grose WF, et al. Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: Two-year followup of a randomized, prospective trial. Diabet Med 1989: 6: 766-71.
209. Riddle MC. Glycemic management of type 2 diabetes: An emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin N Am 2005; 34: 77-98.
210. Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 1997; 20: 1539-42.
211. Bastyr EJ, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, et al. the IOEZ Study Group. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 2000; 23: 1236-41.
212. UKPDSG. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854-65.
213. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non insulin-dependent diabetes mellitus. N Engl J Med 1995; 333(9): 550-4.
214. UKPDSG. A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998; 21(1): 87-92.
215. Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131(3): 182-8.
216. Riddle MC. Combined therapy with insulin plus oral agents: Is there any advantage? An argument in favor. Diabetes Care 2008; 31 (Suppl 2):S130.
217. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24: 758-67.
218. Irl BH, Richard MB, Christopher GP, Eugene W, John BB. A realworld approach to insulin therapy in primary care practice. Clinl Diabetes 2005; 23(2): 78-86.
219. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000; 108(6A): 15S-22S.
220. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-67.
221. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes. JAMA 1997; 278:1663-9.
222. United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998; 128:165-75.
223. Riddle MC. Evening insulin strategy. Diabetes Care 1990; 13: 676-86.
224. Riddle MC. Timely initiation of basal insulin. Am J Med 2004; 116(3A): 3S-9S.
225. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, the UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-6.
226. Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327: 1426-33.
227. Shank ML, DelPrato S, DeFronzo RA. Bedtime insulin/daytime glipizide: Effective therapy for sulfonylurea failures in NIDDM. Diabetes 1995; 44: 165-72.
228. Riddle MC, Schneider J. The Glimepiride Combination Group. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care 1998; 21: 1052-57.
229. Riddle MC, Rosenstock J, Gerich J, the Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-6.
230. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study. Diabetologia 2006; 49: 442-51.
231. Kennedy L, Herman WH, Strange P, Harris A, the GOAL A1c Team. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurements of HbA1c on glycemic control in type 2 diabetes: The Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) Trial. Diabetes Care 2006; 29: 1-8.
232. Hermansen K, Davies M, Derezinski R, Ravn GM, Clauson P, Home P, the Levemir Treat-to-Target Study Group. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin naivc-people with type 2 diabetes. Diabetes Care 2006;29: 1269-74.
233. Landstedt-Hallin L, Adamson U, Arner P, Bolinder J, Lins P-E. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 1995; 18: 1183-6.
234. Raccha D, Bretzel RG, Owens D, Riddle MC. When basal insulin therapy in type 2 diabetes mellitus is not enough - what next? Diabetes Metab Res Rev 2007; 23: 257-64.
235. Del Prato1 S, Nicolucci A, Vespasiani G. Optimising basal plus insulin therapy in type 2 diabetes by telecareassistance for selfmonitoring of blood glucose - the ELEONOR study. Diabetologia (2008) 51:[Suppl1] S1-S588.
236. Lankisch MR, Ferlinzet KC, Leahy JL, Scherbaum WA. Orals plus Apidra and LANTUS (OPAL) study group. Introducing a simplified approach to insulin therapy in type 2 diabetes: A comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008; 10(12):1178-85.
237. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R: Insulin glargine in type 2 patients with suboptimal glycemic control on twice-daily premix insulin: AT.LANTUS Trial Results study (Abstract). Diabetes 2004; 53 (Suppl 2):A473.
238. Roach P, Woodworth JR. Clinical Pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clini Pharmacokinet 2002; 41(13):1043-57.
239. Roach P, Yu L, Arora V for the Humalog Mix25 Study Group. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999; 22:1258-61.
240. Jacobsen LV, Sogaard B, Ris A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamineretarded insulin aspart. Eur J Clin Pharmacol 2000; 56(5):399-403.
241. Boehm BO, Home PD, Brehend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 versus premixed human insulin 30/70 twice daily: A random mixed trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19:393-9.
242. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-9.
243. Raskin P, Allen E, Hollander P. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-5.
244. McSorley PT, Bell PM, Jacobsen LV, Kristensen A, Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: A double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002; 24(4):530-9.
245. Hermansen K, Colombo M, Storgaard H, OStergaard A, Kolendorf K, Madsbad S. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002; 25(5):883-8.
246. M-Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357(17):1716-30.
247. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study. Diabetologia 2007; 50(2):259-67.
248. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type 2 diabetics. Metabolic effects during a 6 mo outpatient trial. Diabetes Care 1993; 161(1):21-31.
249. Kuddlacek S, Schernthaner G. The effect of insulin treatment on HbA1c, body weight and lipids in type 2 diabetic patients with secondary failure to sulfonylureas. A five-year follow-up study. Horm Metab Res 1992; 24:478.
250. Naik RG, Palmer JP. Latent autoimmune diabetes in adults (LADA). Rev Endocr Metab Disord 2003; 4:223-41.
251. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): Definition, characterization, and potential prevention. Diabetes Care 2001; 24:1460-7.
252. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 28 (Suppl 1):S4-S36.
253. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-Management - 2002 Update. Endocr Prac 2002; 8 (Suppl 1):40-82.
254. Francis AJ, Home PD, Hanning I, Alberti KG, TunbridgeWM. Intermediate acting insulin given at bedtime. BMJ (Clin Res Ed) 1983; 286:1173-6.
255. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RB, Jones NP, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43.
256. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
257. Garg S, Zisser HC, Schwartz S, Bailey T, Kaplan R, Ellis S, et al. Improvement in glycemic excursions with a transcutaneous, realtime continuous glucose sensor. Diabetes Care 2006; 29:44-50.
258. Leiva AD, Hernando ME. Telemedical artificial pancreas. Diabetes Care 2009; 3: (Suppl 2): S211-6.